Enterprise Value
4.556B
Cash
93.74M
Avg Qtr Burn
N/A
Short % of Float
2.27%
Insider Ownership
59.78%
Institutional Own.
29.04%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PEMRYDI RTU® Details Small cell lung cancer, Malignant pleural/peritoneal mesothelioma | Approved Update | |
Lisdexamfetamine Dimesylate Details Attention deficit hyperactivity disorder | Approved Quarterly sales | |
RELEUKO® (filgrastim-ayow) Details Chemotherapy-induced neutropenia | Approved Quarterly sales | |
Xyrem® (sodium oxybate) Generic Details Narcolepsy | Approved Quarterly sales | |
OTC NARCAN® HCI Nasal Spray Details Opioid overdose | Approved Quarterly sales | |
IPX203 Details Parkinson's disease | NDA Acceptance for review |